Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
Open Access
- 10 January 2015
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 23 (4) , 1137-1143
Abstract
Pegfilgrastim is a pegylated form of filgrastim, a recombinant protein of granulocyte colony-stimulating factor, that is used to reduce the risk of febrile neutropenia (FN). Here, we report the results of a phase III trial of pegfilgrastim in breast cancer patients receiving docetaxel and cyclophosphamide (TC) chemotherapy.Keywords
This publication has 18 references indexed in Scilit:
- Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysisSupportive Care in Cancer, 2012
- 5167 POSTER A Multicenter Randomized Phase II Study of KRN125 (Pegfilgrastim) to Determine the Optimal Dosage in Japanese Breast Cancer Patients Receiving TAC TreatmentEuropean Journal of Cancer, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related PharmacogenomicsJournal of Clinical Oncology, 2009
- Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer PatientsJapanese Journal of Clinical Oncology, 2009
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimenAnnals of Oncology, 2006
- First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III StudyJournal of Clinical Oncology, 2005
- Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide StudyJournal of Clinical Oncology, 2004
- Evidence‐Based Recommendations for Antimicrobial Use in Febrile Neutropenia in Japan: Executive SummaryClinical Infectious Diseases, 2004